Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc (LCTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 318,575
  • Shares Outstanding, K 168,558
  • Annual Sales, $ 1,830 K
  • Annual Income, $ -20,650 K
  • 60-Month Beta 1.71
  • Price/Sales 97.48
  • Price/Cash Flow N/A
  • Price/Book 2.58
Trade LCTX with:

Options Overview Details

View History
  • Implied Volatility 112.63% ( -80.86%)
  • Historical Volatility 92.90%
  • IV Percentile 75%
  • IV Rank 29.77%
  • IV High 204.18% on 02/25/21
  • IV Low 73.82% on 12/09/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 292
  • Volume Avg (30-Day) 446
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 7,204
  • Open Int (30-Day) 7,427

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.05
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.8000 +5.00%
on 12/15/21
2.7100 -30.26%
on 12/27/21
+0.0500 (+2.72%)
since 12/14/21
3-Month
1.8000 +5.00%
on 12/15/21
2.7100 -30.26%
on 12/27/21
-0.5000 (-20.92%)
since 10/14/21
52-Week
1.5500 +21.94%
on 03/05/21
3.1316 -39.65%
on 02/17/21
-0.2800 (-12.90%)
since 01/14/21

Most Recent Stories

More News
Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief...

LCTX : 1.8900 (+2.72%)
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026

Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the...

ONCY : 1.6200 (+5.19%)
ONC.TO : 2.02 (+6.32%)
ITCI : 43.07 (+5.13%)
LCTX : 1.8900 (+2.72%)
GILD : 71.77 (-0.15%)
GRTX : 3.44 (+5.20%)
Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that Lineage and its subsidiary, Cell Cure Neurosciences Ltd., have entered into an exclusive worldwide collaboration and...

LCTX : 1.8900 (+2.72%)
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that restoration of...

LCTX : 1.8900 (+2.72%)
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported updated interim results...

LCTX : 1.8900 (+2.72%)
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0.00% and 305.36%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

LCTX : 1.8900 (+2.72%)
Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating...

LCTX : 1.8900 (+2.72%)
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report...

LCTX : 1.8900 (+2.72%)
Analysts Estimate Lineage Cell (LCTX) to Report a Decline in Earnings: What to Look Out for

Lineage Cell (LCTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LCTX : 1.8900 (+2.72%)
OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, reported today that updated interim...

LCTX : 1.8900 (+2.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are...

See More

Key Turning Points

3rd Resistance Point 2.0167
2nd Resistance Point 1.9633
1st Resistance Point 1.9267
Last Price 1.8900
1st Support Level 1.8367
2nd Support Level 1.7833
3rd Support Level 1.7467

See More

52-Week High 3.1316
Fibonacci 61.8% 2.5274
Fibonacci 50% 2.3408
Fibonacci 38.2% 2.1542
Last Price 1.8900
52-Week Low 1.5500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar